Cassava Sciences Correlations
SAVA Stock | USD 26.48 5.70 17.71% |
The current 90-days correlation between Cassava Sciences and Anavex Life Sciences is 0.23 (i.e., Modest diversification). The correlation of Cassava Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Cassava Sciences Correlation With Market
Weak diversification
The correlation between Cassava Sciences and DJI is 0.3 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cassava Sciences and DJI in the same portfolio, assuming nothing else is changed.
Cassava |
Moving against Cassava Stock
0.46 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.45 | GILD | Gilead Sciences | PairCorr |
0.43 | KZR | Kezar Life Sciences | PairCorr |
0.39 | EWTX | Edgewise Therapeutics | PairCorr |
0.45 | MLYS | Mineralys Therapeutics, | PairCorr |
0.45 | RVMD | Revolution Medicines Sell-off Trend | PairCorr |
0.44 | AMLX | Amylyx Pharmaceuticals | PairCorr |
0.4 | SRZN | Surrozen | PairCorr |
0.38 | MNPR | Monopar Therapeutics | PairCorr |
0.35 | AKRO | Akero Therapeutics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cassava Stock performing well and Cassava Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cassava Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ANVS | 3.16 | (0.51) | 0.00 | (0.50) | 0.00 | 6.62 | 20.79 | |||
AXSM | 1.72 | 0.13 | 0.04 | 0.32 | 1.89 | 4.10 | 13.67 | |||
RVPH | 4.89 | 0.70 | 0.07 | (0.60) | 5.88 | 10.71 | 38.61 | |||
MCRB | 4.68 | 0.01 | (0.02) | 0.25 | 5.68 | 10.00 | 28.84 | |||
AVXL | 3.48 | 0.43 | 0.15 | 0.31 | 3.39 | 10.31 | 30.62 | |||
INMB | 3.39 | (0.63) | 0.00 | (0.14) | 0.00 | 5.78 | 22.66 | |||
BIVI | 7.37 | 1.04 | 0.08 | 9.67 | 10.68 | 11.91 | 133.33 | |||
CGTX | 4.29 | (0.86) | 0.00 | (0.46) | 0.00 | 8.89 | 36.32 | |||
CVAC | 2.34 | (0.38) | 0.00 | (0.20) | 0.00 | 4.45 | 16.27 | |||
RETA | 2.22 | 0.21 | 0.02 | (1.50) | 3.31 | 5.24 | 28.80 |
Cassava Sciences Corporate Management
Christopher JD | Company VP | Profile | |
Lindsay Burns | Senior Neuroscience | Profile | |
Christopher Cook | Sr Counsel | Profile | |
James MD | Chief Officer | Profile | |
Eric Schoen | Chief Officer | Profile | |
Nadav MD | Chief Director | Profile |